US2010272654A1PendingUtilityA1

Levalbuterol salt

Assignee: SEPRACOR INCPriority: Dec 10, 2002Filed: Jul 9, 2010Published: Oct 28, 2010
Est. expiryDec 10, 2022(expired)· nominal 20-yr term from priority
A61P 11/08A61K 9/008C07C 215/60A61K 9/14A61P 11/00A61P 11/06C07B 2200/07A61M 2202/0484A61M 2202/0488C07B 2200/13C07C 59/255C09K 3/30A61K 31/205A61M 15/009A61M 2202/064A61M 15/002A61K 9/00
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.

Claims

exact text as granted — not AI-modified
1 - 29 . (canceled) 
     
     
         30 . A method of treating bronchospasm, which comprises administering to a patient a pharmaceutical composition comprising an effective amount of levalbuterol-L-tartrate using a metered dose inhaler, wherein the levalbuterol-L-tartrate is in the form of micronized crystals. 
     
     
         31 . The method of  claim 30 , wherein the micronized crystals of levalbuterol-L-tartrate are in the form of needle-like particles. 
     
     
         32 . The method of  claim 30 , wherein the levalbuterol-L-tartrate is a hemitartrate. 
     
     
         33 . The method of  claim 30 , wherein the pharmaceutical composition further comprises a propellant. 
     
     
         34 . The method of  claim 33 , wherein the propellant is 1,1,1,2-tetrafluoroethane. 
     
     
         35 . The method of  claim 30 , wherein the pharmaceutical composition further comprises a surfactant. 
     
     
         36 . The method of  claim 35 , wherein the surfactant is oleic acid. 
     
     
         37 . The method of  claim 30 , wherein the pharmaceutical composition further comprises a co-solvent. 
     
     
         38 . The method of  claim 37 , wherein the co-solvent is ethanol. 
     
     
         39 . The method of  claim 38 , wherein the ethanol is dehydrated ethanol. 
     
     
         40 . The method of  claim 30 , wherein the pharmaceutical composition is adapted for administration of from about 45 μg to about 90 μg levalbuterol free base per actuation.

Join the waitlist — get patent alerts

Track US2010272654A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.